Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer.
Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer.
复制标题
DOI：
10.3390/cancers14071755
复制
发表时间：
2022-03-30
期刊：
影响因子：
5.2
通讯作者：
Poultsides GA
中科院分区：
文献类型：
--
作者：
Ahmad MU;Javadi C;Poultsides GA
全球可切除的近端胃、胃食道交界处(GEJ)和远端食道癌的五年生存率从30%到60%不等。新辅助和/或围手术期治疗已经成为一种治疗工具，可以改善手术患者的选择、手术的可切除性和疾病的局部控制。因此，治疗策略从20世纪80年代末的第一次试验演变为2015年更新的关键交叉试验。本文综述了目前有关食道腺癌、食管鳞癌和近端胃的新辅助治疗和/或围手术期治疗的临床试验和治疗建议。几十年来，可切除的近端胃、胃食道交界处(GEJ)和远端食道癌的新辅助治疗策略已经演变。治疗建议根据组织学类型--鳞状细胞癌(SCC)与腺癌(AC)--以及肿瘤的确切位置而有所不同。对这一领域近期和较早的临床试验进行了严格的回顾。以紫杉烷或氟嘧啶为基础的化疗同时进行的新辅助放化疗对食道远端的AC和SCC以及GEJ都有既定的作用。胃AC围手术期化疗的使用是基于FLOT4和MAGIC试验；然而，新辅助化疗在这种情况下的有效性还需要进一步评估。鉴于进一步疾病控制的需要，重点介绍了目前正在进行的评估化疗、靶向治疗、免疫治疗和放射治疗的其他临床试验。
The five-year survival for resectable proximal gastric, gastroesophageal junction (GEJ), and distal esophageal cancer ranges from 30 to 60% globally. Neoadjuvant and/or perioperative therapy has emerged as a treatment tool to improve patient selection for surgery, resectability, and locoregional control of the disease. As a result, treatment strategies have evolved from the first trials in the late 1980s to the pivotal CROSS trial updated in 2015. The review summarizes current clinical trials and treatment recommendations with regard to neoadjuvant and/or perioperative therapy for patients with adenocarcinoma and squamous cell carcinoma of the distal esophagus, GEJ, and proximal stomach. Neoadjuvant treatment strategies for resectable proximal gastric, gastroesophageal junction (GEJ), and distal esophageal cancer have evolved over several decades. Treatment recommendations differ based on histologic type—squamous cell carcinoma (SCC) versus adenocarcinoma (AC)—as well as the exact location of the tumor. Recent and older clinical trials in this area were critically reviewed. Neoadjuvant chemoradiation with concurrent taxane- or fluoropyrimidine-based chemotherapy has an established role for both AC and SCC of the distal esophagus and GEJ. The use of perioperative chemotherapy for gastric AC is based on the FLOT4 and MAGIC trials; however, the utility of neoadjuvant chemoradiation in this setting requires further evaluation. Additional clinical trials evaluating chemotherapy, targeted therapy, immunotherapy, and radiation that are currently in process are highlighted, given the need for further disease control.
登录
查看更多内容
影响因子：
51.1
作者：
Cats, Annemieke;Jansen, Edwin P. M.;Verheij, Marcel
通讯作者：
Verheij, Marcel
3 种以紫杉醇为基础的放化疗方案对局部晚期食管鳞状细胞癌患者的比较：一项随机临床试验
影响因子：
13.8
作者：
Ai D;Ye J;Wei S;Li Y;Luo H;Cao J;Zhu Z;Zhao W;Lin Q;Yang H;Zheng X;Zhou J;Huang G;Li L;Li J;Zhang Z;Zhou G;Gu D;Du M;Mo M;Jia H;Zhang Z;Zhao K
通讯作者：
Zhao K
影响因子：
7.7
作者：
DeWitt, John M.;Murthy, S. Krishna;Fowers, Kirk
通讯作者：
Fowers, Kirk
影响因子：
45.3
作者：
Allum, William H.;Stenning, Sally P.;Langley, Ruth E.
通讯作者：
Langley, Ruth E.
DOI：
10.1007/s00259-018-4099-8
发表时间：
2018-12
影响因子：
9.1
作者：
Bensch F;Brouwers AH;Lub-de Hooge MN;de Jong JR;van der Vegt B;Sleijfer S;de Vries EGE;Schröder CP
通讯作者：
Schröder CP